lerodalcibep
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cardiovascular Disease With Mention of Arteriosclerosis
Conditions
Cardiovascular Disease With Mention of Arteriosclerosis, Elevated Cholesterol, Familial Hypercholesterolemia
Trial Timeline
Dec 3, 2020 → Dec 31, 2025
NCT ID
NCT04798430About lerodalcibep
lerodalcibep is a phase 3 stage product being developed by Medpace for Cardiovascular Disease With Mention of Arteriosclerosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04798430. Target conditions include Cardiovascular Disease With Mention of Arteriosclerosis, Elevated Cholesterol, Familial Hypercholesterolemia.
What happened to similar drugs?
9 of 20 similar drugs in Cardiovascular Disease With Mention of Arteriosclerosis were approved
Approved (9) Terminated (2) Active (9)
Hype Score Breakdown
Clinical
17
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05234775 | Phase 3 | Completed |
| NCT04797104 | Phase 3 | Completed |
| NCT04797247 | Phase 3 | UNKNOWN |
| NCT04806893 | Phase 3 | UNKNOWN |
| NCT04798430 | Phase 3 | Recruiting |
Competing Products
20 competing products in Cardiovascular Disease With Mention of Arteriosclerosis